ASX Health Stocks: Emyria to create wearable device for psychedelics, while Telix gets FDA nod
Health & Biotech
Health & Biotech
Link copied to
The ASX 200 Health Index (XHJ) is trading higher by 0.92% at the time of writing, compared to the broader index which is down by 0.22%.
Cannabis-based medtech company, Emyria Limited (ASX:EMD), has signed an agreement with Seattle-based Cydelic to collaborate on creating technologies that track psychedelic-assisted patients.
Both companies plan to work across all of Emyria’s psychedelic-assisted therapy programs, providing Emyria with a wearable and biometric data using Cydelic’s technology.
The wearable device will be used to capture unique biometric data that can assist with real-time dose response analysis of psychedelic therapy patients.
Emyria’s Phase 2b MDMA therapy trial for severe Post Traumatic Stress Disorder (PTSD) will be the first program to incorporate Cydelic technology.
It’s also one of the first programs in the world to incorporate remote patient monitoring in MDMA therapy, the company said.
Shares in EMD came out of a trading halt and initially rose at the opening bell, but a short time ago were trading around 10% lower at 33c.
Telix Pharmaceuticals (ASX:TLX) says the US FDA has approved its lead prostate cancer imaging product, Illuccix .
Illuccix is a kit for the preparation of gallium-68 (68Ga) gozetotide, also known as PSMA-11 injection used in prostrate cancer diagnosis.
With a distribution network of more than 140 pharmacies through its agreements with Cardinal Health and PharmaLogic, Telix will now be able to provide Illuccix to more than 85% of eligible PET imaging sites throughout the US.
“Improved imaging can provide physicians with the insights to determine the most appropriate treatment pathway,” commented Dr. Christian Behrenbruch, CEO of Telix.
“It will also give patients in the US access to a specific and sensitive imaging tool for the detection of prostate cancer throughout the body,” he said.
Medicinal cannabis company, Incannex Healthcare (ASX:IHL), says it has completed dosing of participants in the Phase 2 clinical trial of IHL-42X, a CBD-based drug to treat obstructive sleep apnoea (OSA).
The trial will be assessing the effect of three doses of IHL-42X in reducing the “apnoea hypopnoea index” as compared to placebo in patients with the disease.
“OSA remains a significantly unmet medical need, and can lead to a variety of cardiovascular complications, with no FDA approved pharmacotherapies,” says Joel Latham, CEO of Incannex.
Singular Health (ASX:SHG) will engage in a $539k research and development (R&D) project to develop a “Surface Scan and Model extension” for its 3Dicom software.
Supported by the CSIRO and the Innovative Manufacturing Cooperative Research Centre (“MCRC), the artificial intelligence (AI) powered software will add 3D surface scans to 3Dicom’s existing CT/MRI capabilities.
Brain injury specialist, HitIQ Limited (ASX:HIQ), has signed an exclusive partnership with Bupa Dental Care, Australia’s largest dental network, to offer HIQ’s concussion management technology.
Under the deal, the HITIQ smart mouthguard technology will be offered exclusively for 12 months through Bupa Dental Care’s network and customer base.
Bupa Dental Care will commence a marketing campaign in early CY 2022, where customers can access the technology at many practices across its Australian network.
Australian Clinical Labs (ASX:ACL) has now completed the acquisition of Medlab Pathology as initially announced in November.
At Stockhead we tell it like it is. While HitIQ and Incannex Healthcare are Stockhead advertisers, they did not sponsor this article.